The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.
The Canadian Network for Psychedelic-Assisted Cancer Therapy launches a systematic research program to study psychedelic assisted therapy cancer patients experiencing demoralization syndrome. This multi-phase initiative prioritizes training, safety…
GLP-1 Receptor Agonist Clinical Evidence: New Findings
GLP-1 receptor agonist clinical trial evidence provides critical insights into safety and emerging side effects. This evidence supports clinicians in monitoring patient outcomes effectively. Understanding these findings helps optimize GLP-1 therapy…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The temporary scheduling of 2-fluorodeschloroketamine reflects regulatory efforts to control emerging synthetic ketamine analogs. This DEA action addresses public health concerns related to novel psychoactive substances. Clinicians should stay informed…
Schedule I Drug Classification: 3 Times Science Was Ignored
This meme isn’t exaggeration—it’s history repeating itself in policy. The Schedule I drug classification was meant to indicate substances with a high potential for abuse and no accepted medical use. But as science has evolved, that definition…